Scientists discover why Ozempic may not work for some people

GLP-1 drugs such as Ozempic, Wegovy and Mounjaro have transformed weight-loss treatment over the past four years. But clinicians have long been puzzled by the fact that one patient may lose substantial weight while another, on the same drug, sees no effect. Science Daily reports on new research that may explain this "response heterogeneity". The finding could open the door to more personalised obesity treatment.

The researchers examined how the density and activity of GLP-1 receptors in a specific region of the brainstem vary from person to person. According to Science Daily, individuals with fewer such receptors, or with genetic variants that weaken their response to the drug, show limited treatment success. The group commonly described in clinics as "non-responders" largely overlaps with this profile, the report says.

GLP-1 drugs work primarily by activating brain circuits that regulate satiety. Slowing gastric emptying and boosting insulin secretion are only part of the picture; the bulk of the effect comes from the brain signals that reduce hunger. Science Daily highlights the study's central conclusion: if the drug cannot bind strongly enough to its brain receptors, the weight-loss effect is also weakened.

The research combined animal models with human cell cultures. Scientists divided mice into two groups: those with abundant receptors and those whose receptors had been genetically diluted. After administering a GLP-1 drug, mice in the first group ate notably less food, while those in the second were almost unaffected. The result aligns with what clinicians have long observed.

In human samples, known mutations in the receptor gene were screened. Science Daily reports that people with certain mutation profiles had significantly lower response rates and concentrate in the group of patients who lose little or no weight on the drug. The study lays the groundwork for a future genetic test that could be done before initiating treatment.

The clinical implications are important. Current guidelines prescribe GLP-1 drugs to all eligible patients and assess response after three to six months. Given the drugs' high cost and the burden of side effects, this is inefficient. Science Daily writes that a future biomarker test would help predict in advance which patients are likely to benefit from trying the drug for weight loss.

Experts received the study with the caveat that genetic differences are not the only explanation for GLP-1 failure. Behavioural factors, adherence, co-medication and metabolic status, the Science Daily report notes, also influence response. Receptor genetics is a major piece of the puzzle but not the whole picture.

Another implication is for future drug design. If the receptor binding is weak in some patients, then next-generation drugs with stronger binding or alternative mechanisms could be developed. The dual- and triple-hormone candidates now in trials are seen as steps in that direction. Science Daily framed these as alternatives aimed at patients who do not respond to single-hormone therapy.

For the broader narrative around obesity, the finding strengthens the scientific case against treating the disease as a matter of "willpower". According to Science Daily, the study shows that failing to respond reflects a biological profile rather than insufficient effort or motivation. That message carries weight for obesity treatment adherence and for reducing stigma around the disease.

The broader takeaway, as Science Daily frames it, is that the second decade of obesity drugs is shifting the question from "which drug?" to "which drug for which patient?". The cost of genetic testing remains a barrier, but the trajectory of clinical science points toward a personalised approach that is likely to become permanent. This study adds an important brick on that path.